Filing Flows › Gilead Sciences (GILD) › Q2 2025
Gilead Sciences (GILD) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Gilead Sciences (GILD) reported revenue of $7.1B for the second quarter 2025 (Q2 2025), +2% from a year earlier and +6% from the quarter before. Operating margin was 34.9%, net earnings $2.0B (27.7% of revenue).
Gilead Sciences, Q2 2025: revenue $7.1B (+2% year over year), operating margin 34.9%, net earnings $2.0B, operating cash flow $827M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.1B | +6% | +2% |
| Operating profit | $2.5B | +11% | -6% |
| Net earnings | $2.0B | +49% | +21% |
| Operating cash flow | $827M | -53% | -38% |
| Free cash flow | $720M | — | -40% |
What changed
Revenue was $7.1B in Q2 2025, up 2% year over year and up 6% from the previous quarter. Biktarvy was the largest line at 50% of revenue. Biktarvy added $0.30B year over year (up 9%), 233% of the total change. Sofosbuvir/Velpatasvir declined 28%.
Operating profit was $2.5B, a 34.9% margin (down 3.1 points year over year). Operating profit fell $0.17B even though revenue rose $0.13B versus a year earlier, so costs grew faster than sales. Total costs grew 7% against revenue growth of 2%. The fastest-growing cost line was Other operating costs (+561%). Net earnings were $2.0B, up 21% year over year. The effective tax rate was 19.3%.
Operating cash flow was $0.83B (down 38% year over year), 42% of net earnings. Non-cash charges added back $0.09B of depreciation and $0.23B of share-based compensation. Working capital and other items used $1.5B. After purchases of property, plant and equipment ($0.11B), free cash flow as the company reports it was $0.72B.
Questions
What was Gilead Sciences' revenue in the second quarter 2025?
Gilead Sciences (GILD) reported revenue of $7.1B for the second quarter 2025 (Q2 2025), +2% from a year earlier and +6% from the quarter before.
Was Gilead Sciences profitable in the second quarter 2025?
Operating profit was $2.5B (34.9% of revenue) and net earnings $2.0B.
Source: Gilead Sciences 10-Q on SEC EDGAR.